SG11201700770PA - Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment - Google Patents

Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment

Info

Publication number
SG11201700770PA
SG11201700770PA SG11201700770PA SG11201700770PA SG11201700770PA SG 11201700770P A SG11201700770P A SG 11201700770PA SG 11201700770P A SG11201700770P A SG 11201700770PA SG 11201700770P A SG11201700770P A SG 11201700770PA SG 11201700770P A SG11201700770P A SG 11201700770PA
Authority
SG
Singapore
Prior art keywords
car
cancer treatment
antigen receptor
chimeric antigen
chimeric
Prior art date
Application number
SG11201700770PA
Inventor
Jennifer Brogdon
Saar Gill
David Glass
Saad Kenderian
Andreas Loew
Joan Mannick
Michael Milone
Leon Murphy
David L Porter
Marco Ruella
Yongqiang Wang
Qilong Wu
Jiquan Zhang
Original Assignee
Novartis Ag
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag
Publication of SG11201700770PA publication Critical patent/SG11201700770PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
SG11201700770PA 2014-08-19 2015-08-19 Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment SG11201700770PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014084696 2014-08-19
CN2014090508 2014-11-06
PCT/US2015/045898 WO2016028896A1 (en) 2014-08-19 2015-08-19 Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment

Publications (1)

Publication Number Publication Date
SG11201700770PA true SG11201700770PA (en) 2017-03-30

Family

ID=54011902

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700770PA SG11201700770PA (en) 2014-08-19 2015-08-19 Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment

Country Status (22)

Country Link
US (4) US9815901B2 (en)
EP (2) EP3183268B1 (en)
JP (2) JP7084138B2 (en)
KR (1) KR102616429B1 (en)
CN (2) CN112410363A (en)
AU (2) AU2015305531B2 (en)
BR (1) BR112017003104A2 (en)
CA (1) CA2958553A1 (en)
CO (1) CO2017001573A2 (en)
DK (1) DK3183268T3 (en)
ES (1) ES2791248T3 (en)
HU (1) HUE049218T2 (en)
IL (2) IL250362B (en)
LT (1) LT3183268T (en)
MX (1) MX2017002205A (en)
MY (1) MY189028A (en)
PL (1) PL3183268T3 (en)
PT (1) PT3183268T (en)
RU (2) RU2020117196A (en)
SG (1) SG11201700770PA (en)
TW (2) TW202140557A (en)
WO (1) WO2016028896A1 (en)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
CA2864489C (en) * 2012-02-22 2023-08-08 The Trustees Of The University Of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
TW201446794A (en) 2013-02-20 2014-12-16 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
ES2760023T3 (en) 2013-02-20 2020-05-12 Univ Pennsylvania Cancer treatment using humanized anti-EGFRvIII chimeric antigen receptor
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JP2016537345A (en) 2013-11-13 2016-12-01 ノバルティス アーゲー MTOR inhibitors for enhancing immune responses
EP3083964B1 (en) 2013-12-19 2022-01-26 Novartis AG Human mesothelin chimeric antigen receptors and uses thereof
EP3087101A4 (en) 2013-12-20 2017-12-06 Novartis AG Regulatable chimeric antigen receptor
ES2963718T3 (en) 2014-01-21 2024-04-01 Novartis Ag Antigen-presenting capacity of CAR-T cells enhanced by co-introduction of co-stimulatory molecules
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CR20160506A (en) 2014-03-28 2017-03-10 Xencor Inc Bispecific Antibodies that bind to CD38 and CD3
KR102487608B1 (en) 2014-04-07 2023-01-12 노파르티스 아게 Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3171882A1 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using a cll-1 chimeric antigen receptor
TWI719942B (en) 2014-07-21 2021-03-01 瑞士商諾華公司 Treatment of cancer using a cd33 chimeric antigen receptor
CA2955386A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
CN112410363A (en) 2014-08-19 2021-02-26 诺华股份有限公司 anti-CD 123 Chimeric Antigen Receptor (CAR) for cancer therapy
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
ES2891332T3 (en) 2014-09-17 2022-01-27 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3204777A1 (en) 2014-10-08 2017-08-16 Novartis AG Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
DK3223845T3 (en) 2014-11-26 2021-08-16 Xencor Inc HETERODIMERING ANTIBODIES BINDING CD3 AND CD20
KR20170087514A (en) * 2014-12-03 2017-07-28 주노 쎄러퓨티크스 인코퍼레이티드 Methods and compositions for adoptive cell therapy
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10273300B2 (en) 2014-12-29 2019-04-30 The Trustees Of The University Of Pennsylvania Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3270936A4 (en) 2015-03-17 2018-08-08 Chimera Bioengineering Inc. Smart car devices, de car polypeptides, side cars and uses thereof
HUE059218T2 (en) 2015-04-08 2022-11-28 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
ES2948133T3 (en) * 2015-04-17 2023-08-31 Novartis Ag Methods to improve the efficiency and expansion of cells expressing a chimeric antigen receptor
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
KR20180021137A (en) * 2015-06-25 2018-02-28 아이셀 진 테라퓨틱스 엘엘씨 Chimeric antigen receptor (CAR), compositions and methods for their use
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
US20180325953A1 (en) * 2015-11-09 2018-11-15 Aperisys, Inc. Modified immune cells and uses thereof
CN108699136B (en) 2015-12-07 2022-03-18 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and PSMA
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
MA44140A (en) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc CHEMERICAL ANTIGEN RECEPTOR (CAR) AGAINST MESOTHELIN AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTI-CANCER THERAPY
RU2018127657A (en) 2015-12-30 2020-01-31 Новартис Аг TYPES OF THERAPY BASED ON IMMUNO EFFECTIVE CELLS WITH IMPROVED EFFICIENCY
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017180565A1 (en) * 2016-04-14 2017-10-19 Immunomedics, Inc. Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers
WO2017181119A2 (en) 2016-04-15 2017-10-19 Novartis Ag Compositions and methods for selective protein expression
EP3458077A4 (en) 2016-05-17 2020-04-01 Chimera Bioengineering Inc. Methods for making novel antigen binding domains
EP3469001A4 (en) * 2016-06-09 2020-05-06 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN109562126A (en) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 Chimeric antigen receptor (CAR), composition and its application method
CN116063545A (en) 2016-06-28 2023-05-05 Xencor股份有限公司 Heterodimeric antibodies that bind somatostatin receptor 2
CA3030837A1 (en) * 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018017928A1 (en) * 2016-07-22 2018-01-25 Seattle Genetics, Inc. Combination therapy using a cd19-adc and rchp
AU2017301826A1 (en) * 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
SG11201900677SA (en) * 2016-07-28 2019-02-27 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107793481A (en) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 A kind of Chimerical receptor part for targetting people CD123 and its application
CN110121352B (en) 2016-09-01 2020-12-11 嵌合体生物工程公司 GOLD-optimized CAR T-cells
WO2018057943A1 (en) * 2016-09-23 2018-03-29 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
EP3519577A1 (en) 2016-09-28 2019-08-07 Novartis AG Porous membrane-based macromolecule delivery system
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
EP3526241A1 (en) 2016-10-14 2019-08-21 Xencor, Inc. Il15/il15r heterodimeric fc-fusion proteins
US11840569B2 (en) * 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
AU2017363970A1 (en) 2016-11-23 2019-06-20 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN107058390A (en) * 2017-01-17 2017-08-18 上海交通大学医学院附属第九人民医院 A kind of slow virus carrier, recombinant slow virus plasmid, virus and viral application
EP3570850A4 (en) * 2017-01-18 2020-10-14 Thalia Papayannopoulou Compositions and methods for transplant recipient conditioning
ES2912408T3 (en) 2017-01-26 2022-05-25 Novartis Ag CD28 compositions and methods for therapy with chimeric receptors for antigens
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CN110582288A (en) 2017-02-28 2019-12-17 恩多塞特公司 Compositions and methods for CAR T cell therapy
BR112019018124A2 (en) 2017-03-22 2020-04-07 Intellia Therapeutics Inc compositions and methods for immunooncology
US11104737B2 (en) 2017-03-28 2021-08-31 Rigel Pharmaceuticals, Inc. ACVR2A-specific antibody and method of treatment of muscle atrophy
CN110582280B (en) 2017-03-31 2024-03-19 小利兰·斯坦福大学托管委员会 Methods for treating T cell depletion by inhibiting or modulating T cell receptor signaling
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3630839A1 (en) * 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
US11434290B2 (en) 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
CN111132733A (en) 2017-06-30 2020-05-08 Xencor股份有限公司 Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain
WO2019018525A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cd123-binding chimeric antigen receptors
CN109423495A (en) * 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 A kind of pair of targeting Chimeric antigen receptor and application thereof
CA3070861A1 (en) * 2017-09-22 2019-03-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced nfkb signaling
EP3688143A4 (en) * 2017-09-26 2021-09-22 Longwood University Pd1-specific chimeric antigen receptor as an immunotherapy
WO2019072824A1 (en) * 2017-10-09 2019-04-18 Cellectis Improved anti-cd123 car in universal engineered immune t cells
CN111629749A (en) 2017-10-18 2020-09-04 诺华股份有限公司 Compositions and methods for selective protein degradation
CN109694854B (en) * 2017-10-20 2023-11-21 亘喜生物科技（上海）有限公司 Universal chimeric antigen receptor T cell preparation technology
RU2020116579A (en) 2017-10-25 2021-11-25 Новартис Аг METHODS FOR OBTAINING CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US20200371091A1 (en) * 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
MA51210A (en) 2017-12-01 2020-10-07 Juno Therapeutics Inc METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
JP7394058B2 (en) 2017-12-21 2023-12-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Universal reporter cell assay for specificity testing of novel antigen-binding moieties
WO2019122060A1 (en) * 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Car-t cell assay for specificity test of novel antigen binding moieties
WO2019134950A1 (en) * 2018-01-04 2019-07-11 Miltenyi Biotec Gmbh Chimeric antigen receptor specific for bdca2 antigen
CN112292138A (en) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Methods of use of CAR T cells
JP2021518747A (en) 2018-02-13 2021-08-05 キメラ・バイオエンジニアリング，インコーポレーテッド Regulation of gene expression using RNA destabilizing elements
US20190284288A1 (en) * 2018-03-19 2019-09-19 The Regents Of The University Of Michigan Compositions and methods for t-cell and cytokine activation
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
KR20210010862A (en) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
EP3817767A1 (en) * 2018-07-02 2021-05-12 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
EP3831936A4 (en) 2018-07-31 2022-04-13 Thyas Co. Ltd. Method for producing regenerated t cell population via ips cells
CA3229942A1 (en) * 2018-08-01 2020-02-06 Nantkwest, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
US20210324042A1 (en) * 2018-08-01 2021-10-21 Nantkwest, Inc. Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
BR112021003305A2 (en) 2018-08-31 2021-05-25 Novartis Ag methods for producing cells that express chimeric antigen receptor
WO2020061048A1 (en) * 2018-09-17 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
CA3113058A1 (en) * 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
CN110950954B (en) * 2018-09-26 2021-06-25 重庆精准生物技术有限公司 anti-CD 123 humanized single-chain antibody and application thereof
JP2022503959A (en) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド IL-12 heterodimer FC-fusion protein
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
US20210401886A1 (en) * 2018-10-31 2021-12-30 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN109754394B (en) * 2018-12-28 2021-02-23 上海联影智能医疗科技有限公司 Three-dimensional medical image processing device and method
WO2020125806A1 (en) 2018-12-17 2020-06-25 Shanghai United Imaging Intelligence Co., Ltd. Systems and methods for image segmentation
BR112021011874A2 (en) 2018-12-20 2021-09-08 Novartis Ag DOSAGE SCHEME AND PHARMACEUTICAL COMBINATION INCLUDING DERIVATIVES OF 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
MX2021009763A (en) 2019-02-15 2021-09-08 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof.
KR20210129672A (en) 2019-02-15 2021-10-28 노파르티스 아게 Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN109777783B (en) * 2019-02-20 2023-07-04 上海尚泰生物技术有限公司 CXCR 2-expressing CAR-NK92 cell, preparation method and application thereof
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2020198678A1 (en) * 2019-03-27 2020-10-01 University Of Virginia Patent Foundation Priming with targeted activated t cells can enhance chemo responsiveness of cancer cells
JP2022526194A (en) 2019-04-10 2022-05-23 エレベートバイオ テクノロジーズ，インコーポレイテッド FLT3-specific chimeric antigen receptor and its usage
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220195007A1 (en) * 2019-04-12 2022-06-23 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with cd20 safety switch
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
EP3966242A1 (en) 2019-05-04 2022-03-16 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof
WO2020251046A1 (en) 2019-06-14 2020-12-17 サイアス株式会社 Medicinal composition
AU2020334884A1 (en) 2019-08-18 2022-02-17 Chimera Bioengineering, Inc. Combination therapy with gold controlled transgenes
WO2021041486A1 (en) * 2019-08-27 2021-03-04 Janssen Biotech, Inc. Chimeric antigen receptor system and uses thereof
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20210246215A1 (en) * 2019-11-08 2021-08-12 Humanigen, Inc. Epha3 directed car-t cells for treatment of tumors
AU2020393912A1 (en) 2019-11-26 2022-06-09 Novartis Ag Chimeric antigen receptors binding BCMA and CD19 and uses thereof
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
JP2023515211A (en) 2020-02-27 2023-04-12 ノバルティス アーゲー Method for producing chimeric antigen receptor-expressing cells
MX2022010604A (en) 2020-02-27 2022-09-09 Novartis Ag Methods of making chimeric antigen receptor-expressing cells.
US20210277149A1 (en) * 2020-03-06 2021-09-09 Mustang Bio, Inc. Anti-idiotype antibodies and methods of using the same
CN113493522B (en) * 2020-04-03 2023-04-28 重庆精准生物技术有限公司 Bispecific chimeric antigen receptor and uses thereof
CN113493521B (en) * 2020-04-03 2023-05-05 重庆精准生物技术有限公司 CD19 and CD123 targeting double-target chimeric antigen receptor and application thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN115917317A (en) 2020-06-08 2023-04-04 詹森生物科技公司 Cell-based assay for determining in vitro tumor killing activity of immune cells expressing chimeric antigens
IL298473A (en) 2020-06-11 2023-01-01 Novartis Ag Zbtb32 inhibitors and uses thereof
BR112022026202A2 (en) 2020-06-23 2023-01-17 Novartis Ag DOSAGE REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONE DERIVATIVES
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CN116134027A (en) 2020-08-03 2023-05-16 诺华股份有限公司 Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof
CN111995688B (en) * 2020-08-13 2024-01-16 金鑫 Bispecific chimeric antigen receptor targeting CD123 and NKG2D ligand and application thereof
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
AU2021376354A1 (en) 2020-11-04 2023-06-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
MX2023005609A (en) 2020-11-13 2023-05-29 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells.
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
CN117157319A (en) 2021-03-09 2023-12-01 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and CLDN6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2022250431A1 (en) 2021-05-25 2022-12-01 주식회사 박셀바이오 Monobody-based chimeric antigen receptor and immune cell including same
WO2022267843A1 (en) * 2021-06-21 2022-12-29 Westlake University Library construction method based on long overhang sequence ligation
WO2023010126A2 (en) * 2021-07-29 2023-02-02 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
CN114933654A (en) * 2021-08-16 2022-08-23 上海优替济生生物医药有限公司 Antibodies targeting CD123, chimeric antigen receptors and uses thereof
WO2023021477A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
US20230338424A1 (en) * 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN116990504B (en) * 2023-09-27 2023-12-01 苏州旭光科星抗体生物科技有限公司 Double antibody sandwich ELISA kit for detecting human soluble CD4

Family Cites Families (410)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DE3381783D1 (en) 1982-03-03 1990-09-13 Genentech Inc HUMAN ANTITHROMBIN III, DNA SEQUENCES THEREFOR, EXPRESSION AND CLONING VECTORS CONTAINING SUCH SEQUENCES AND THEREFORE TRANSFORMED CELL CULTURES, METHOD FOR EXPRESSING HUMAN ANTITHROMBIN III AND THESE CONTAINERS.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
JPH021556A (en) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd Hybrid antibody and production thereof
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP0517895B1 (en) 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
EP0580751A1 (en) 1991-04-19 1994-02-02 Schering Corporation Subunit of the human interleukin-3 receptor
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU676150B2 (en) 1992-01-23 1997-03-06 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
ATE295420T1 (en) 1992-02-06 2005-05-15 Chiron Corp MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
ATE165113T1 (en) 1992-05-08 1998-05-15 Creative Biomolecules Inc MULTI-VALUE CHIMERIC PROTEINS ANALOGUE AND METHOD FOR THE APPLICATION THEREOF
PT1498427E (en) 1992-08-21 2010-03-22 Univ Bruxelles Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
JP4105761B2 (en) 1993-11-19 2008-06-25 アボット・ラボラトリーズ Semi-synthetic analog immunomodulator of rapamycin (macrolide)
PT734389E (en) 1993-12-17 2000-09-29 Novartis Ag US RAPAMICINE DERIVATIVES AS IMMUNOSUPRESSORS
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
ES2185705T3 (en) 1994-05-02 2003-05-01 Bernd Groner BIFUNCTIONAL PROTEIN, PREPARATION AND USE.
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
CA2209300C (en) 1995-02-24 2011-06-28 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
JPH11508126A (en) 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー Multimeric protein
KR100400620B1 (en) 1995-06-09 2004-02-18 노파르티스 아게 Rapamycin Derivatives
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
DK0894135T3 (en) 1996-04-04 2004-12-06 Unilever Nv Multivalent and multispecific antigen binding protein
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP0937095A4 (en) 1996-10-25 1999-12-22 Cell Genesys Inc Targeted cytolysis of cancer cells
KR100566859B1 (en) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Selection of proteins using rna-protein fusions
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
PT1012280E (en) 1997-06-11 2005-02-28 Borean Pharma As TRIMMING MODULE
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
ATE461282T1 (en) 1997-10-27 2010-04-15 Bac Ip Bv MULTIVALENT ANTIGEN-BINDING PROTEINS
DK1049787T3 (en) 1998-01-23 2005-04-04 Vlaams Interuniv Inst Biotech Antibody derivatives with multiple uses
JP2002502607A (en) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
HUP9900956A2 (en) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Single-chain multiple antigen-binding molecules, their preparation and use
DE69925909T2 (en) 1998-04-15 2006-05-11 Brigham & Women's Hospital, Inc., Boston T-cell inhibiting receptor compositions and their use
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
JP2002521053A (en) 1998-07-28 2002-07-16 マイクロメット アーゲー Heteromini body
JP2002524081A (en) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Fusion receptor specific for prostate-specific membrane antigen and uses thereof
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
EP1171596A1 (en) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
ATE264863T1 (en) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-EPIRAPALOGUE
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
KR20030032922A (en) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA3036031C (en) 2000-03-06 2021-04-13 Craig T. Jordan A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
ES2637801T3 (en) 2000-04-11 2017-10-17 Genentech, Inc. Multivalent antibodies and uses thereof
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
IL136511A0 (en) 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CA2417185A1 (en) 2000-07-25 2002-01-31 Shui-On Leung Multivalent target binding protein
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
JP4261907B2 (en) 2000-10-20 2009-05-13 中外製薬株式会社 Low molecular weight agonist antibody
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
AU2002256390B2 (en) 2001-04-30 2007-08-30 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
ES2276735T3 (en) 2001-09-14 2007-07-01 Affimed Therapeutics Ag SINGLE CHAIN MULTIMERIC FV ANTIBODIES IN TANDEM.
ATE434040T1 (en) 2001-10-01 2009-07-15 Dyax Corp MULTI-CHAIN EUKARYONTIC DISPLAY VECTORS AND USES THEREOF
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
GB0208104D0 (en) 2002-04-09 2002-05-22 Univ Dundee Method
WO2003087163A1 (en) 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
MXPA05012475A (en) 2003-05-23 2006-05-25 Wyeth Corp Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof.
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Fused protein composition
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
JP2007518399A (en) 2003-12-02 2007-07-12 ジェンザイム コーポレイション Compositions and methods for diagnosing and treating lung cancer
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
WO2006107617A2 (en) 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US7754482B2 (en) 2004-05-27 2010-07-13 The Trustees Of The University Of Pennsylvania Artificial antigen presenting cells and uses therefor
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
JP2008512352A (en) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド Novel tetravalent bispecific antibody
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
EP3530321A1 (en) 2004-12-10 2019-08-28 Peter MacCallum Cancer Institute Methods and compositions for adoptive immunotherapy
PT2343320T (en) 2005-03-25 2018-01-23 Gitr Inc Anti-gitr antibodies and uses thereof
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2707152T3 (en) 2005-04-15 2019-04-02 Macrogenics Inc Covalent diabodies and uses thereof
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US8124084B2 (en) 2005-05-17 2012-02-28 University Of Connecticut Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1757622B1 (en) 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
GEP20115199B (en) 2005-10-07 2011-04-11 Exelixis Inc Phosphatidylinositol 3-kinase inhibitors and their use
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
WO2007062466A1 (en) 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
EP2251034B1 (en) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
AU2007207785B2 (en) 2006-01-13 2013-11-14 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL- 15 and IL- 15R-alpha genes for expression in mammalian cells
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp Gitr antibodies for the treatment of cancer
JP2009526857A (en) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー Functional antibody
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
WO2007112362A2 (en) 2006-03-24 2007-10-04 The Regents Of The University Of California Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
PL1999154T3 (en) 2006-03-24 2013-03-29 Merck Patent Gmbh Engineered heterodimeric protein domains
JP5144499B2 (en) 2006-03-31 2013-02-13 中外製薬株式会社 Antibody modification method for purifying bispecific antibodies
EP2799449A1 (en) 2006-05-25 2014-11-05 Bayer Intellectual Property GmbH Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
MX2009004664A (en) 2006-11-02 2009-10-12 Daniel J Capon Hybrid immunoglobulins with moving parts.
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
US9212230B2 (en) 2007-03-29 2015-12-15 Genmab A/S Bispecific antibodies and methods for production thereof
CA2967847C (en) 2007-03-30 2023-08-01 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
SI2170959T1 (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
EP3124046B1 (en) 2007-07-12 2019-12-25 GITR, Inc. Combination therapies employing gitr binding molecules
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc Multispecific epitope binding proteins and uses thereof
EP2178914A2 (en) 2007-08-15 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
CA2703947C (en) 2007-10-26 2018-12-04 Governing Council Of The University Of Toronto Therapeutic and diagnostic methods using tim-3
JP2011504740A (en) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． Amino acid sequence directed to heterodimeric cytokines and / or their receptors, and polypeptides containing the same
CA2706419A1 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs binding il-13
AU2008331436A1 (en) 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262504A1 (en) 2008-02-21 2010-12-22 AstraZeneca AB Combination therapy 238
US8379824B2 (en) 2008-03-06 2013-02-19 At&T Intellectual Property I, Lp Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
EP2310508A1 (en) 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tgf-b antagonist multi-target binding proteins
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
PE20110435A1 (en) 2008-08-25 2011-07-20 Amplimmune Inc ANTAGONIST COMPOSITIONS OF PD-1
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
PL3006459T3 (en) 2008-08-26 2022-01-17 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010030002A1 (en) 2008-09-12 2010-03-18 国立大学法人三重大学 Cell capable of expressing exogenous gitr ligand
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CN114835812A (en) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
WO2010085660A2 (en) 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
JPWO2010110346A1 (en) 2009-03-24 2012-10-04 独立行政法人理化学研究所 Leukemia stem cell marker
CA2950529C (en) 2009-04-03 2019-04-30 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (s) inhibitors
KR101732201B1 (en) 2009-04-27 2017-05-02 교와 핫꼬 기린 가부시키가이샤 Anti-il-3r antibody for use in treatment of blood tumor
CN102459346B (en) 2009-04-27 2016-10-26 昂考梅德药品有限公司 The method manufacturing heteromultimers molecule
SI2424896T1 (en) 2009-04-30 2015-12-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti ceacam1 antibodies and methods of using same
EP2464377B1 (en) 2009-08-14 2016-07-27 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of il-15 to increase thymic output and to treat lymphopenia
ES2788869T3 (en) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anti-GITR antibodies
EP2470212A4 (en) 2009-10-01 2013-12-04 Csl Ltd Method of treatment of philadelphia chromosome positive leukaemia
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
TR201904484T4 (en) 2009-11-03 2019-05-21 Hope City Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection.
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
AU2011212794B2 (en) 2010-02-04 2014-06-26 The Trustees Of The University Of Pennsylvania ICOS critically regulates the expansion and function of inflammatory human Th17 cells
EA201201435A1 (en) 2010-04-20 2013-04-30 Генмаб А/С HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
EP2582390B1 (en) 2010-06-15 2014-11-19 CSL Limited Immunotherapeutic method involving cd123 (il-3r ) antibodies and immunostimulating complex
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
AU2011274510A1 (en) 2010-07-09 2013-01-24 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
AR084706A1 (en) 2010-07-16 2013-06-05 Piramal Life Sciences Ltd SUBSTITUTED DERIVATIVES OF IMIDAZOQUINOLINAS AS QUINASE INHIBITORS AND PROCESS FOR PREPARATION
WO2012012667A2 (en) 2010-07-21 2012-01-26 Sangamo Biosciences, Inc. Methods and compositions for modification of a hla locus
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
EP2632482A4 (en) 2010-10-27 2015-05-27 Baylor College Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PT3214091T (en) 2010-12-09 2019-01-11 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2791716T3 (en) 2010-12-14 2020-11-05 Univ Maryland T cells expressing the universal anti-label chimeric antigen receptor and methods for the treatment of cancer
KR20140004174A (en) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for treating cancer
BR112013024395B1 (en) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center ADOPTIVE COMPOSITIONS OF CELL IMMUNOTHERAPY AND METHOD FOR MANUFACTURING SUCH COMPOSITION
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
EP3323833B1 (en) 2011-04-01 2019-12-04 Memorial Sloan-Kettering Cancer Center T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
NZ710810A (en) 2011-04-08 2016-09-30 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
CN102796198A (en) 2011-05-26 2012-11-28 中国医学科学院血液病医院 Fusion protein of anti-cluster of differetiation (CD3) antibody Fv segment and interleukin 3, method for preparing fusion protein and application of fusion protein
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9469851B2 (en) 2011-07-25 2016-10-18 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of DUX4
WO2013019615A2 (en) 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
SG10201606288TA (en) 2011-08-11 2016-09-29 Intellikine Llc Kinase inhibitor polymorphs
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
EP2756521A4 (en) 2011-09-16 2015-04-22 Univ Pennsylvania Rna engineered t cells for the treatment of cancer
US20140255363A1 (en) 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
RU2644243C2 (en) 2011-10-20 2018-02-08 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Chimeric antigenic receptors to cd22
LT2771364T (en) 2011-10-27 2019-09-10 Genmab A/S Production of heterodimeric proteins
CA2892371C (en) 2011-12-01 2021-01-19 The Brigham And Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
DK2794658T3 (en) 2011-12-19 2017-06-19 Synimmune Gmbh BISPECIFIC ANTIBODY MOLECULE
SG11201404285VA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CA2864688C (en) 2012-02-22 2023-09-05 The Trustees Of The University Of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
CA2864489C (en) 2012-02-22 2023-08-08 The Trustees Of The University Of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
ES2924722T3 (en) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Immunofusion binding of bispecific scFv (BIf) to CD123 and CD3
PE20190844A1 (en) 2012-05-25 2019-06-17 Emmanuelle Charpentier MODULATION OF TRANSCRIPTION WITH ADDRESSING RNA TO GENERIC DNA
CN104507537A (en) 2012-07-13 2015-04-08 宾夕法尼亚大学董事会 Compositions and methods for regulating car t cells
EP3584256A1 (en) 2012-07-13 2019-12-25 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
CN104427997B (en) 2012-07-13 2020-12-11 宾夕法尼亚大学董事会 Toxicity management of antitumor Activity of CARS
WO2014011988A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
IN2015DN00139A (en) 2012-07-13 2015-06-12 Univ Pennsylvania
US20160235787A1 (en) 2012-07-13 2016-08-18 The Trustees Of The University Of Pennsylvania Epitope Spreading Associated with CAR T-Cells
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
BR112015002816A8 (en) 2012-08-20 2023-04-18 Hutchinson Fred Cancer Res METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
EP2906684B8 (en) * 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
KR102229873B1 (en) 2012-10-12 2021-03-19 더 브리검 앤드 우먼즈 하스피털, 인크. Enhancement of the immune response
SG10201801969TA (en) 2012-12-12 2018-04-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
EP3252160B1 (en) 2012-12-12 2020-10-28 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014110591A1 (en) 2013-01-14 2014-07-17 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
TW201446794A (en) 2013-02-20 2014-12-16 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
ES2760023T3 (en) 2013-02-20 2020-05-12 Univ Pennsylvania Cancer treatment using humanized anti-EGFRvIII chimeric antigen receptor
US20160031996A1 (en) 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
CN111218429A (en) 2013-03-14 2020-06-02 西奈山伊坎医学院 Newcastle disease virus and uses thereof
WO2014138819A1 (en) 2013-03-14 2014-09-18 Csl Limited Agents that neutralize il-3 signaling and uses thereof
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CA2925061C (en) 2013-09-26 2023-02-14 Ablynx Nv Bispecific nanobodies
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3083964B1 (en) 2013-12-19 2022-01-26 Novartis AG Human mesothelin chimeric antigen receptors and uses thereof
EP3087101A4 (en) 2013-12-20 2017-12-06 Novartis AG Regulatable chimeric antigen receptor
ES2767423T3 (en) * 2014-01-13 2020-06-17 Hope City Chimeric antigen receptors (CARS) with mutations in the Fc spacer region and methods for their use
ES2963718T3 (en) 2014-01-21 2024-04-01 Novartis Ag Antigen-presenting capacity of CAR-T cells enhanced by co-introduction of co-stimulatory molecules
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CA2939711C (en) 2014-02-21 2020-09-29 Cellectis Method for in situ inhibition of regulatory t cells
ES2939760T3 (en) 2014-03-15 2023-04-26 Novartis Ag Cancer treatment using a chimeric receptor for antigens
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
MX370272B (en) 2014-03-19 2019-12-09 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy.
KR102487608B1 (en) 2014-04-07 2023-01-12 노파르티스 아게 Treatment of cancer using anti-cd19 chimeric antigen receptor
TWI719942B (en) 2014-07-21 2021-03-01 瑞士商諾華公司 Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (en) 2014-07-21 2017-09-28 ノバルティス アーゲー Low immunoenhancing dose of mTOR inhibitor and CAR combination
US20170226495A1 (en) 2014-07-21 2017-08-10 Novartis Ag Sortase molecules and uses thereof
EP3171882A1 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using a cll-1 chimeric antigen receptor
US20170274014A1 (en) 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
CA2955386A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3660042B1 (en) 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
CN112410363A (en) 2014-08-19 2021-02-26 诺华股份有限公司 anti-CD 123 Chimeric Antigen Receptor (CAR) for cancer therapy
ES2891332T3 (en) 2014-09-17 2022-01-27 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3204777A1 (en) 2014-10-08 2017-08-16 Novartis AG Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016061368A1 (en) 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
US10273300B2 (en) 2014-12-29 2019-04-30 The Trustees Of The University Of Pennsylvania Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
HUE059218T2 (en) 2015-04-08 2022-11-28 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
ES2948133T3 (en) 2015-04-17 2023-08-31 Novartis Ag Methods to improve the efficiency and expansion of cells expressing a chimeric antigen receptor
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
EP3350320A1 (en) 2015-09-17 2018-07-25 Novartis AG Car t cell therapies with enhanced efficacy
MA44140A (en) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc CHEMERICAL ANTIGEN RECEPTOR (CAR) AGAINST MESOTHELIN AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTI-CANCER THERAPY
RU2018127657A (en) 2015-12-30 2020-01-31 Новартис Аг TYPES OF THERAPY BASED ON IMMUNO EFFECTIVE CELLS WITH IMPROVED EFFICIENCY
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201900677SA (en) 2016-07-28 2019-02-27 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
EP3523290A4 (en) 2016-09-30 2020-07-29 Novartis AG Immune effector cell therapies with enhanced efficacy
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
RU2019133286A (en) 2017-03-22 2021-04-22 Новартис Аг BIOMARKERS AND THERAPIES BASED ON T-CELLS WITH CAR WITH INCREASED EFFICIENCY
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN111629749A (en) 2017-10-18 2020-09-04 诺华股份有限公司 Compositions and methods for selective protein degradation
RU2020116579A (en) 2017-10-25 2021-11-25 Новартис Аг METHODS FOR OBTAINING CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR
JP2021502979A (en) 2017-11-15 2021-02-04 ノバルティス アーゲー BCMA targeting chimeric antigen receptor, CD19 targeting chimeric antigen receptor and combination therapy
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
US20200061113A1 (en) 2018-04-12 2020-02-27 Novartis Ag Chimeric antigen receptor therapy characterization assays and uses thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20200085869A1 (en) 2018-05-16 2020-03-19 Novartis Ag Therapeutic regimens for chimeric antigen receptor therapies
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2020393912A1 (en) 2019-11-26 2022-06-09 Novartis Ag Chimeric antigen receptors binding BCMA and CD19 and uses thereof
CA3162892A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
EP3183268A1 (en) 2017-06-28
RU2017108903A3 (en) 2019-03-14
AU2021218185A1 (en) 2021-09-09
CO2017001573A2 (en) 2017-07-19
US11591404B2 (en) 2023-02-28
BR112017003104A2 (en) 2017-12-05
PT3183268T (en) 2020-05-15
ES2791248T3 (en) 2020-11-03
CN107108744A (en) 2017-08-29
AU2015305531A1 (en) 2017-02-23
HUE049218T2 (en) 2020-10-28
US20160068601A1 (en) 2016-03-10
CA2958553A1 (en) 2016-02-25
JP7084138B2 (en) 2022-06-14
TW202140557A (en) 2021-11-01
JP2017530694A (en) 2017-10-19
IL250362B (en) 2021-01-31
US20210002377A1 (en) 2021-01-07
RU2017108903A (en) 2018-09-21
KR102616429B1 (en) 2023-12-26
US10703819B2 (en) 2020-07-07
US9815901B2 (en) 2017-11-14
PL3183268T3 (en) 2020-09-07
WO2016028896A1 (en) 2016-02-25
IL280204A (en) 2021-03-01
TWI719946B (en) 2021-03-01
KR20170039307A (en) 2017-04-10
JP2021184715A (en) 2021-12-09
EP3183268B1 (en) 2020-02-12
RU2020117196A (en) 2020-10-15
AU2015305531B2 (en) 2021-05-20
LT3183268T (en) 2020-06-10
RU2724999C2 (en) 2020-06-29
US20230220090A1 (en) 2023-07-13
EP3712171A1 (en) 2020-09-23
CN112410363A (en) 2021-02-26
MX2017002205A (en) 2017-08-21
IL250362A0 (en) 2017-03-30
TW201617367A (en) 2016-05-16
CN107108744B (en) 2020-09-25
US20180312595A1 (en) 2018-11-01
MY189028A (en) 2022-01-20
DK3183268T3 (en) 2020-05-11

Similar Documents

Publication Publication Date Title
IL280204A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
IL280215A (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
IL272572B (en) Antibody compositions for tumor treatment
IL250161A0 (en) Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
HK1220536A1 (en) User interface for payments
SG11201606790XA (en) Chimeric antigen receptor
IL251630A0 (en) Combination therapy for use in cancer therapy
FI3169703T4 (en) Chimeric antigen receptor and its use
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
HK1225791A1 (en) Cell surface prostate cancer antigen for diagnosis
IL250507A0 (en) Anti-ck8 antibodies for use in the treatment of cancers
GB201409761D0 (en) Chimeric antigen receptor
GB201403481D0 (en) Chimeric antigen receptor